Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422015 | 1.00 | S100A4 (0.34) | S100A4ACHEMEN1CDC25BKMT2A | |
| SCHEMBL30171202 | 0.64 | IDO1 (0.30) | CDC25B | |
| SCHEMBL8323390 | 0.63 | CDC25B (0.33) | S100A4MEN1CDC25BKMT2A | |
| SCHEMBL8346897 | 0.61 | MEN1 (0.36) | S100A4MEN1CDC25BKMT2A | |
| SCHEMBL527160 | 0.60 | ABCG2 (0.46) | S100A4ACHEMEN1CDC25BKMT2A | |
| SCHEMBL30624821 | 0.60 | MEN1 (0.31) | S100A4MEN1CDC25BKMT2A | |
| SCHEMBL2359460 | 0.60 | IDO1 (0.44) | S100A4MEN1CDC25BKMT2A | |
| SCHEMBL879050 | 0.60 | CDC25B (0.39) | S100A4MEN1CDC25BKMT2A | |
| SCHEMBL2026326 | 0.60 | MEN1 (0.39) | S100A4MEN1CDC25BKMT2A | |
| SCHEMBL31131321 | 0.60 | LMNA (0.45) | S100A4MEN1CDC25BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230065522-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065522-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | PARP2, PARP1, PARP3 | S100A4 785/4885ACHE 4647/4885MEN1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.